JPWO2021098757A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021098757A5 JPWO2021098757A5 JP2022524620A JP2022524620A JPWO2021098757A5 JP WO2021098757 A5 JPWO2021098757 A5 JP WO2021098757A5 JP 2022524620 A JP2022524620 A JP 2022524620A JP 2022524620 A JP2022524620 A JP 2022524620A JP WO2021098757 A5 JPWO2021098757 A5 JP WO2021098757A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- variable region
- chain variable
- pharmaceutical combination
- combination product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013066 combination product Substances 0.000 claims 13
- 229940127555 combination product Drugs 0.000 claims 13
- 239000000427 antigen Substances 0.000 claims 8
- 102000036639 antigens Human genes 0.000 claims 8
- 108091007433 antigens Proteins 0.000 claims 8
- 239000012634 fragment Substances 0.000 claims 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 230000028993 immune response Effects 0.000 claims 4
- 230000001965 increasing effect Effects 0.000 claims 3
- 230000004936 stimulating effect Effects 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 102000049823 human TIGIT Human genes 0.000 claims 2
- 210000000822 natural killer cell Anatomy 0.000 claims 2
- 239000000047 product Substances 0.000 claims 2
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 230000007503 antigenic stimulation Effects 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000001461 cytolytic effect Effects 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 102000050320 human TNFRSF4 Human genes 0.000 claims 1
- 230000036737 immune function Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 230000036963 noncompetitive effect Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000009257 reactivity Effects 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 230000002459 sustained effect Effects 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2019/120033 | 2019-11-21 | ||
| CN2019120033 | 2019-11-21 | ||
| PCT/CN2020/129992 WO2021098757A1 (en) | 2019-11-21 | 2020-11-19 | Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tigit antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023502323A JP2023502323A (ja) | 2023-01-24 |
| JPWO2021098757A5 true JPWO2021098757A5 (ru) | 2023-11-29 |
Family
ID=75980305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022524620A Pending JP2023502323A (ja) | 2019-11-21 | 2020-11-19 | 抗ｔｉｇｉｔ抗体との組合せで抗ｏｘ４０抗体を用いる癌治療の方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230002500A1 (ru) |
| EP (1) | EP4061846A4 (ru) |
| JP (1) | JP2023502323A (ru) |
| KR (1) | KR20220103709A (ru) |
| CN (1) | CN114746446A (ru) |
| AU (1) | AU2020385499A1 (ru) |
| BR (1) | BR112022009265A2 (ru) |
| CA (1) | CA3157042A1 (ru) |
| IL (1) | IL293118A (ru) |
| MX (1) | MX2022006148A (ru) |
| WO (1) | WO2021098757A1 (ru) |
| ZA (1) | ZA202204422B (ru) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020023746A2 (pt) | 2018-05-23 | 2021-02-17 | Beigene, Ltd. | anticorpo, composição farmacêutica, método para tratar câncer, ácido nucleico isolado, vetor, célula hospedeira, processo para a produção de um anticorpo e reagente de diagnóstico |
| TW202216778A (zh) | 2020-07-15 | 2022-05-01 | 美商安進公司 | Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷 |
| WO2024012584A1 (en) * | 2022-07-15 | 2024-01-18 | Beigene Switzerland Gmbh | Methods of cancer treatment using anti-tigit antibodies |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ563193A (en) * | 2005-05-09 | 2010-05-28 | Ono Pharmaceutical Co | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| SG10201402815VA (en) * | 2008-04-09 | 2014-09-26 | Genentech Inc | Novel compositions and methods for the treatment of immune related diseases |
| AU2015327868A1 (en) * | 2014-10-03 | 2017-04-20 | Novartis Ag | Combination therapies |
| TW201619200A (zh) * | 2014-10-10 | 2016-06-01 | 麥迪紐有限責任公司 | 人類化抗－ｏｘ４０抗體及其用途 |
| RU2017119428A (ru) * | 2014-11-06 | 2018-12-06 | Дженентек, Инк. | Комбинированная терапия, включающая применение агонистов, связывающихся с ох40, и ингибиторов tigit |
| US9644032B2 (en) * | 2015-05-29 | 2017-05-09 | Bristol-Myers Squibb Company | Antibodies against OX40 and uses thereof |
| US20200407445A1 (en) * | 2017-07-27 | 2020-12-31 | Iteos Therapeutics Sa | Anti-tigit antibodies |
| EP3704159A1 (en) * | 2017-11-01 | 2020-09-09 | Bristol-Myers Squibb Company | Immunostimulatory agonistic antibodies for use in treating cancer |
| CN112292397B (zh) * | 2017-11-24 | 2023-01-31 | 祐和医药科技(北京)有限公司 | 抗ox40抗体及其用途 |
| CN111393529B (zh) * | 2018-01-29 | 2022-02-22 | 康源博创生物科技(北京)有限公司 | 与ox40l非竞争结合的抗ox40抗体 |
| BR112020023746A2 (pt) * | 2018-05-23 | 2021-02-17 | Beigene, Ltd. | anticorpo, composição farmacêutica, método para tratar câncer, ácido nucleico isolado, vetor, célula hospedeira, processo para a produção de um anticorpo e reagente de diagnóstico |
-
2020
- 2020-11-19 JP JP2022524620A patent/JP2023502323A/ja active Pending
- 2020-11-19 EP EP20889442.8A patent/EP4061846A4/en active Pending
- 2020-11-19 IL IL293118A patent/IL293118A/en unknown
- 2020-11-19 AU AU2020385499A patent/AU2020385499A1/en active Pending
- 2020-11-19 CA CA3157042A patent/CA3157042A1/en active Pending
- 2020-11-19 BR BR112022009265A patent/BR112022009265A2/pt unknown
- 2020-11-19 US US17/778,660 patent/US20230002500A1/en active Pending
- 2020-11-19 MX MX2022006148A patent/MX2022006148A/es unknown
- 2020-11-19 KR KR1020227014833A patent/KR20220103709A/ko active Search and Examination
- 2020-11-19 CN CN202080080865.7A patent/CN114746446A/zh active Pending
- 2020-11-19 WO PCT/CN2020/129992 patent/WO2021098757A1/en unknown
-
2022
- 2022-04-20 ZA ZA2022/04422A patent/ZA202204422B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022002520A5 (ru) | ||
| JP2023113893A5 (ru) | ||
| JP2024020298A5 (ru) | ||
| JP2020528750A5 (ru) | ||
| JP2024037894A5 (ru) | ||
| FI3394103T3 (fi) | Anti-PD-1-vasta-aineiden ja bispesifisten anti-CD20-/anti-CD3-vasta-aineiden yhdistelmä syövän hoitoon | |
| JP2020515247A5 (ru) | ||
| JP2019535254A5 (ja) | 抗ｐｄ−ｌ１抗体および変異型 | |
| JP2021531764A5 (ru) | ||
| RU2019111722A (ru) | Антитела против siglec-15 и способы их применения | |
| JP2018527952A5 (ru) | ||
| FI3932951T3 (fi) | Menetelmiä ihosyövän hoitamiseksi antamalla PD-1-inhibiittoria | |
| FI3810281T3 (fi) | Menetelmiä syövän hoitamiseksi bispesifisillä anti-CD3XMUC16-vasta-aineilla ja anti-PD-1-vasta-aineilla | |
| JP2017514461A5 (ru) | ||
| RU2018124319A (ru) | Новые антитела к клаудину и способы их применения | |
| JPWO2019246514A5 (ru) | ||
| JP2020515577A5 (ru) | ||
| RU2018123709A (ru) | Новые антитела для лечения онкологических заболеваний | |
| RU2019104980A (ru) | Анти-icos антитела | |
| JP2021512652A5 (ru) | ||
| JP2020522280A5 (ru) | ||
| US11224654B2 (en) | Combinations and uses thereof | |
| JPWO2019246356A5 (ru) | ||
| JPWO2021098757A5 (ru) | ||
| NZ740351A (en) | Immunity enhancing agent for cancer by allergin-1 antagonist |